Verification evidence is still being completed.
PDF / print export
Lipum
Umea, Sweden
- Verified lead
- Ola Sandborgh
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Inflammation, Chronic Disease, Biopharma, Antibody Development, and Preclinical Therapeutics
- Review cycle
- May 2026
- Full address
- Tvistevagen 48 C, 907 36 Umea, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Lipum investor page confirming the Umea address.
- Editorial note
- Lipum is published because official company materials confirm current leadership, Umea operating address, and a real chronic-inflammation therapeutics platform.
Inflammation, Chronic Disease, Biopharma, Antibody Development, and Preclinical Therapeutics
Official leadership disclosure, Official Umea address disclosure, Biopharma platform claim
Lipum is published because official company materials confirm current leadership, Umea operating address, and a real chronic-inflammation therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Umea, Sweden
Lipum
Inflammation, Chronic Disease, Biopharma, Antibody Development, and Preclinical Therapeutics · Preclinical biopharma platform
Lipum runs inflammation therapeutics development, biopharma platform work, and preclinical program development in Umea, Sweden.
- Lead
- Ola Sandborgh (verified ↗)
- Address
- Tvistevagen 48 C, 907 36 Umea, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 22 Mar 2026 (2mo ago)
- Scale
- Preclinical biopharma platform
- Capabilities
- Inflammation Therapeutics Development · Biopharma Platform Work · Preclinical Program Development
- Founded
- 2010
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Ola Sandborgh
CEO
Full addressTvistevagen 48 C, 907 36 Umea, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Preclinical biopharma platform
Umea, Sweden. Inflammation, Chronic Disease, Biopharma, Antibody Development, and Preclinical Therapeutics. Review completed on 22 Mar 2026.
Swedish corporate and therapeutics-development oversight
Official leadership disclosure, Official Umea address disclosure, Biopharma platform claim
Inflammation, Chronic Disease, Biopharma, Antibody Development, and Preclinical Therapeutics
Lipum is published because official company materials confirm current leadership, Umea operating address, and a real chronic-inflammation therapeutics platform.
Editorial note
Lipum is published because official company materials confirm current leadership, Umea operating address, and a real chronic-inflammation therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Inflammation Therapeutics Development
Biopharma Platform Work
Preclinical Program Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Biopharma R&D workflow
Inflammation program infrastructure
Preclinical development systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
22 Mar 2026: Executive identity confirmed via official management disclosure.
22 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Lipum located?
- Lipum operates from Tvistevagen 48 C, 907 36 Umea, Sweden, Umea, Sweden.
- Who runs Lipum?
- Lipum is led by Ola Sandborgh, CEO. Verified 22 Mar 2026.
- What does Lipum do?
- Lipum runs inflammation therapeutics development, biopharma platform work, and preclinical program development in Umea, Sweden. Core capabilities: Inflammation Therapeutics Development, Biopharma Platform Work, Preclinical Program Development.
Editorial context
Related technical briefs
Briefs that name Umea as a covered market or city.